Phosphorylated Tau Levels in Donated Blood
The University of Texas Health Science Center, Houston · with National Institute on Aging (NIA) · NCT07157839
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Any age listed · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 250
- US sites recruiting
- 1
- Study start
- August 28, 2025
- Record last updated
- February 11, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Alzheimer's disease (AD) is characterized by the accumulation of tau pathology, and blood-based biomarkers such as phosphorylated tau-217 (pTau217) have been identified as sensitive and specific predictors of AD risk. Recent studies suggest that individuals with elevated pTau217 levels may be at increased risk for developing AD and cognitive dysfunction. This observational study will examine donated human plasma samples to determine whether some units of donated blood contain abnormally elevated pTau217 concentrations. The overarching goal is to evaluate whether transfusion of blood with higher pTau217 may pose risks to recipients and whether such units should be avoided in clinical use.
Conditions: Alzheimer&Amp;#39;s Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- The plasma sample from donators.
Exclusion Criteria
- None.
Recruiting US locations
University of Texas Health Science Center at Houston
Houston, TX 77030
Site contact: Zhongcong Xie · 7135006207 · Zhongcong.Xie@uth.tmc.edu
Study contacts (from the official record)
- Zhongcong Xie, M.D., Ph.D. · 17135006207 · Zhongcong.Xie@uth.tmc.edu
Similar studies in Texas
All neurology studies in Texas →- RecruitingHealthy volunteersPhase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Eli Lilly and Company
- Location
- Austin, TX + 7 other US sites
- Eligibility basics
- Ages 30–85
- RecruitingHealthy volunteersPhase 1
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
Suninflam Inc
- Location
- Cypress, TX + 9 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1Overnight stay mentioned
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
- Location
- Fredericksburg, TX
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersEarly Phase 1
Pharmacological Modulation of Brain Oscillations in Memory Processing
University of Texas Southwestern Medical Center
- Location
- Dallas, TX
- Eligibility basics
- Ages 18–55